274 related articles for article (PubMed ID: 22008916)
1. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice.
Qiu K; Falk DJ; Reier PJ; Byrne BJ; Fuller DD
Mol Ther; 2012 Jan; 20(1):21-7. PubMed ID: 22008916
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
[TBL] [Abstract][Full Text] [Related]
3. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
[TBL] [Abstract][Full Text] [Related]
4. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
[TBL] [Abstract][Full Text] [Related]
5. Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase.
Cagin U; Puzzo F; Gomez MJ; Moya-Nilges M; Sellier P; Abad C; Van Wittenberghe L; Daniele N; Guerchet N; Gjata B; Collaud F; Charles S; Sola MS; Boyer O; Krijnse-Locker J; Ronzitti G; Colella P; Mingozzi F
Mol Ther; 2020 Sep; 28(9):2056-2072. PubMed ID: 32526204
[TBL] [Abstract][Full Text] [Related]
6. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.
Puzzo F; Colella P; Biferi MG; Bali D; Paulk NK; Vidal P; Collaud F; Simon-Sola M; Charles S; Hardet R; Leborgne C; Meliani A; Cohen-Tannoudji M; Astord S; Gjata B; Sellier P; van Wittenberghe L; Vignaud A; Boisgerault F; Barkats M; Laforet P; Kay MA; Koeberl DD; Ronzitti G; Mingozzi F
Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187643
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
8. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD
Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439
[TBL] [Abstract][Full Text] [Related]
9. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.
Elmallah MK; Falk DJ; Nayak S; Federico RA; Sandhu MS; Poirier A; Byrne BJ; Fuller DD
Mol Ther; 2014 Apr; 22(4):702-12. PubMed ID: 24336173
[TBL] [Abstract][Full Text] [Related]
10. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
Han SO; Li S; Koeberl DD
Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice.
Foley JW; Bercury SD; Finn P; Cheng SH; Scheule RK; Ziegler RJ
Mol Ther; 2010 Sep; 18(9):1584-91. PubMed ID: 20551907
[TBL] [Abstract][Full Text] [Related]
12. Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa
Sellier P; Vidal P; Bertin B; Gicquel E; Bertil-Froidevaux E; Georger C; van Wittenberghe L; Miranda A; Daniele N; Richard I; Gross DA; Mingozzi F; Collaud F; Ronzitti G
J Inherit Metab Dis; 2024 Jan; 47(1):119-134. PubMed ID: 37204237
[TBL] [Abstract][Full Text] [Related]
13. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
14. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.
Han SO; Li S; Brooks ED; Masat E; Leborgne C; Banugaria S; Bird A; Mingozzi F; Waldmann H; Koeberl D
Hum Gene Ther; 2015 Jan; 26(1):26-35. PubMed ID: 25382056
[TBL] [Abstract][Full Text] [Related]
15. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.
Smith BK; Collins SW; Conlon TJ; Mah CS; Lawson LA; Martin AD; Fuller DD; Cleaver BD; Clément N; Phillips D; Islam S; Dobjia N; Byrne BJ
Hum Gene Ther; 2013 Jun; 24(6):630-40. PubMed ID: 23570273
[TBL] [Abstract][Full Text] [Related]
18. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.
Falk DJ; Mah CS; Soustek MS; Lee KZ; Elmallah MK; Cloutier DA; Fuller DD; Byrne BJ
Mol Ther; 2013 Sep; 21(9):1661-7. PubMed ID: 23732990
[TBL] [Abstract][Full Text] [Related]
19. Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.
Hordeaux J; Dubreil L; Robveille C; Deniaud J; Pascal Q; Dequéant B; Pailloux J; Lagalice L; Ledevin M; Babarit C; Costiou P; Jamme F; Fusellier M; Mallem Y; Ciron C; Huchet C; Caillaud C; Colle MA
Acta Neuropathol Commun; 2017 Sep; 5(1):66. PubMed ID: 28874182
[TBL] [Abstract][Full Text] [Related]
20. Neural deficits contribute to respiratory insufficiency in Pompe disease.
DeRuisseau LR; Fuller DD; Qiu K; DeRuisseau KC; Donnelly WH; Mah C; Reier PJ; Byrne BJ
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9419-24. PubMed ID: 19474295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
